Anixa Biosciences, Inc. (ANIX) - Long-Term Debt to Capital

This daily price action for Anixa Biosciences, Inc. (ANIX) on GURU.Markets reflects 0.01, while the business adheres to environmental standards by minimizing toxic emissions in its laboratories. Anixa Biosciences, Inc. (ANIX) relies on partnerships with scientific centers to develop T-cell therapies. Current R&D expenditures are weighing on profitability as the project remains in the clinical testing phase.

This ratio measures the proportion of liabilities with a maturity of more than one year relative to equity, determining the degree of financial leverage and the business's resilience to interest rate changes. By analyzing the level of long-term debt load on capital, an investor assesses the ability of Anixa Biosciences, Inc. (ANIX) to fund T-cell vaccine development and strategic alliances without a critical increase in borrowing costs.